NCT05114421 - Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 9, 2021

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

High Grade Fallopian Tube Serous AdenocarcinomaHigh Grade Ovarian Serous AdenocarcinomaPeritoneal High Grade Serous AdenocarcinomaRecurrent High Grade Fallopian Tube Serous AdenocarcinomaRecurrent High Grade Ovarian Serous AdenocarcinomaRecurrent Primary Peritoneal High Grade Serous Adenocarcinoma

Interventions

DRUG

Lenvatinib

Given PO

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER